Lung Cancer TALK: A Review of Data from the IASLC 2020 World Conference on Lung Cancer - Episode 2

WCLC Updates on the Emergence of ADCs in NSCLC

February 26, 2021
Stephen Liu, MD, Georgetown Lombardi Comprehensive Cancer Center

,
Sarah Goldberg, MD, MPH, Yale School of Medicine

,
Benjamin Levy, MD, Johns Hopkins Sidney Kimmel Cancer Center

,
Heather A. Wakelee, MD, Stanford University Medical Center

Panelists provide insight into emerging clinical trial data on antibody-drug conjugates (ADCs) presented at the IASLC 2020 World Conference on Lung Cancer (WCLC).

Data from the following clinical trials are discussed:

  • OA04.05 - Trastuzumab Deruxtecan in HER2-Overexpressing Metastatic Non–Small Cell Lung Cancer: Interim Results of DESTINY-Lung01
  • OA03.04 - Efficacy and Safety of the Novel HER3-Directed Antibody-Drug Conjugate Patritumab Deruxtecan (HER3-DXd; U3-1402) in EGFR-mutated NSCLC
  • OA03.03 - Datopotamab Deruxtecan (Dato-DXd; DS-1062), a TROP2 ADC, in Patients With Advanced NSCLC: Updated Results of TROPION-PanTumor01 Phase 1 Study
x